IN THE SPOTLIGHT

Medscape Onsite: Riding the Wave of NSCLC Updates From San Diego

Medscape Onsite: Riding the Wave of NSCLC Updates From San Diego

Deciphering the Latest Clinical Data for EGFR-Mutated Advanced NSCLC: Unveiling Expert Insights

Deciphering the Latest Clinical Data for EGFR-Mutated Advanced NSCLC: Unveiling Expert Insights

First-Line Amivantamab Plus Lazertinib Demonstrates Promise in Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer

First-Line Amivantamab Plus Lazertinib Demonstrates Promise in Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Amivantamab Plus Chemotherapy Numerically Improved OS for Patients with EGFR-Mutant, Advanced NSCLC

Second Interim Analysis Results From MARIPOSA-2

Amivantamab Plus Chemotherapy Numerically Improved OS for Patients with EGFR-Mutant, Advanced NSCLC

Second Interim Analysis Results From MARIPOSA-2

Summit Therapeutics Announces Completion of Enrollment in Its Phase III HARMONi Trial in 2L+ EGFRm NSCLC

Summit Therapeutics Announces Completion of Enrollment in Its Phase III HARMONi Trial in 2L+ EGFRm NSCLC

September 2024 FDA Roundup: Key Decisions Drive Oncology Forward

September 2024 FDA Roundup: Key Decisions Drive Oncology Forward

First-line treatment of EGFR-mutated non-small cell lung cancer with brain metastases: a systematic review and meta-analysis

First-line treatment of EGFR-mutated non-small cell lung cancer with brain metastases: a systematic review and meta-analysis

ctDNA EGFRm helps pinpoint who benefits from 1L osimertinib-chemo combo

ctDNA EGFRm helps pinpoint who benefits from 1L osimertinib-chemo combo

Overview of MARIPOSA Study

Overview of MARIPOSA Study

Tagrisso Approved for Stage III Unresectable EGFR-Mutated NSCLC

Tagrisso Approved for Stage III Unresectable EGFR-Mutated NSCLC